Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) fell 6.2% on Monday . The stock traded as low as $4.98 and last traded at $4.95. 4,679,937 shares traded hands during trading, a decline of 71% from the average session volume of 15,996,274 shares. The stock had previously closed at $5.27.
Analyst Ratings Changes
Several research firms recently weighed in on RXRX. Morgan Stanley began coverage on Recursion Pharmaceuticals in a research report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 target price on the stock. Needham & Company LLC reiterated a "buy" rating and set a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Tuesday. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $7.00.
Check Out Our Latest Analysis on RXRX
Recursion Pharmaceuticals Trading Up 1.7%
The business has a fifty day moving average price of $4.82 and a 200 day moving average price of $6.09. The company has a market capitalization of $2.31 billion, a PE ratio of -3.18 and a beta of 0.91. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.11 and a current ratio of 4.11.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported ($0.50) EPS for the quarter, missing analysts' consensus estimates of ($0.44) by ($0.06). The firm had revenue of $14.75 million during the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business's revenue for the quarter was up 7.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.39) earnings per share. Analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 EPS for the current fiscal year.
Institutional Investors Weigh In On Recursion Pharmaceuticals
Several hedge funds have recently modified their holdings of RXRX. AlphaQuest LLC purchased a new stake in shares of Recursion Pharmaceuticals during the 1st quarter valued at about $36,000. GAMMA Investing LLC raised its holdings in shares of Recursion Pharmaceuticals by 39.0% during the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after buying an additional 2,026 shares during the period. Farther Finance Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 21.1% during the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares during the period. NewEdge Advisors LLC raised its holdings in shares of Recursion Pharmaceuticals by 43.7% during the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares during the period. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Recursion Pharmaceuticals during the 4th quarter valued at about $54,000. 89.06% of the stock is currently owned by hedge funds and other institutional investors.
Recursion Pharmaceuticals Company Profile
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
See Also
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.